Promoting mobility and healthy aging in men: a narrative review by Ebeling, PR et al.
1 
 
Working Title: Promoting Mobility and Healthy Ageing in Men: A Narrative Review  
 
Authors: Peter R. Ebeling, MBBS, MD, FRACP, https://orcid.org/0000-0002-2921-
37421; Flavia Cicuttini, MBBS, PhD, MSc, FRACP, https://orcid.org/0000-0002-8200-
16182; David Scott, PhD, BHM, PhD, https://orcid.org/0000-0001-5226-19723;  
Graeme Jones, MBBS, PhD, FRACP, https://orcid.org/0000-0002-9814-00064 
Affiliations: 1School of Clinical Sciences at Monash Health, Monash University, 
Clayton, Victoria, Australia; 2School of Public Health and Preventive Medicine, 
Monash University, Clayton, Victoria, Australia; 3Australian Institute for 
Musculoskeletal Science, The University of Melbourne, Melbourne, Australia; 
4Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia 
Address for correspondence: 
Peter R. Ebeling, MBBS, MD, FRACP 
Professor of Medicine   
School of Clinical Sciences at Monash Health 
Monash University    
Level 5 / Block E, 
Monash Medical Centre 
246 Clayton Road 
Clayton, VIC 3168 
Australia    
Phone: +61 3 8572 2570  
E-mail: peter.ebeling@monash.edu  
 
 
2 
 
ACKNOWLEDGMENTS 
Medical writing support was provided by Diane Sloan, PharmD, of Peloton 
Advantage, LLC, and was funded by an unrestricted educational grant from Pfizer. 
 
CONFLICT OF INTEREST STATEMENT 
PRE has received research funding from Alexion, Amgen, and Eli Lilly and speaker 
honoraria from Amgen. FC declares that they have no conflict of interest. DS has 
received a speaker honorarium from Amgen. GJ declares that they have no conflict 
of interest.  
3 
 
ABSTRACT (Word limit: 150–250; Current word count: 250) 
Purpose: Limitations in mobility are increasingly recognized as a major public health 
problem due to an ageing population and growing number of older individuals 
affected by disabling comorbidities. Despite increasing numbers and debilitating 
consequences, there are no guidelines providing recommendations on strategies to 
maintain mobility for healthy ageing among older men. This narrative review aims to 
fill this literature gap. 
Methods: PubMed, Scopus, and Google Scholar databases were searched using 
predefined search terms. Primary studies, exploratory analyses, cross-sectional 
surveys, meta-analyses, evidence-based clinical reviews, and guidelines from 
nationally recognized societies focusing on mobility in older men and key elements 
including bone, muscle and joint health, and balance were selected. 
Results: Several modifiable and nonmodifiable risk factors have been reported in 
the literature that impact bone, muscle, and joint health and predispose older men to 
falls and fractures. The most common conditions impacting bones, muscles, and 
joints are osteoporosis, sarcopenia, and osteoarthritis, respectively. In addition to 
being key contributors to disability in the elderly, these conditions are all associated 
with a higher mortality risk. Although more studies are required, current evidence 
supports the use of various nonpharmacological (mainly exercise and nutrition) 
and/or pharmacological treatment modalities to help prevent and/or reverse these 
conditions. 
Conclusions: Incorporating lifestyle interventions involving exercise and nutrition at 
a younger age can help prevent the age-related, progressive deterioration in bones, 
muscles, and joints that can reduce mobility in later life. Established barriers to 
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physical activities (e.g., poor health, social isolation) in men are important to consider 
for optimizing outcomes. 
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MINI ABSTRACT 
 
Maintaining mobility is an important aspect of health and well-being in older men. 
This literature review describes several modifiable and nonmodifiable risk factors 
impacting bone, muscle, and joint health. Exercise and nutritional interventions may 
help to prevent the progressive deterioration in bones, muscles, and joints impacting 
mobility in later life. 
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(Word count limit: 10,000; Current count: 4,773) 
INTRODUCTION 
Mobility, defined as the ability to move about independently and safely in one’s 
environment, is an important component of health and quality of life among older 
adults [1]. However, 40% of individuals reported mobility limitations in a recent 
nationally representative survey of insured older adults in the United States (US). 
The prevalence of mobility limitations assessed as severe or moderate were 21.4% 
and 18.4%, respectively, among the study sample of 15,989 older adults with 
Medicare supplemental insurance plans (survey responses were weighted based on 
demographic, socioeconomic, and clinical variables to adjust for potential bias 
associated with survey response and stratified sampling to increase generalizability 
and create a nationally representative study sample) [2]. The authors reported that 
individuals with mobility limitations were more likely to suffer from depression and 
less likely to have ambitious goals, resilience, or social support [2]. 
 
A previous survey of community-dwelling older adults enrolled in Medicare 
demonstrated that mobility limitations were common (present in 45% of the 
population) and strongly associated with development of future functional 
disability/loss of independence and increased healthcare care expenditures and 
utilization [3]. Furthermore, mobility (defined as self-reported ability to walk one-
quarter mile) was shown to be an independent predictor of mortality; across the 12- 
to 16-month follow-up period, mortality rates were 15% for individuals who were 
unable to walk one-quarter mile at baseline, 4% for those with mobility difficulty, and 
2% for those with no mobility limitations. This association remained significant even 
after adjustments were made for multiple confounders including demographics, 
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socioeconomic status, chronic conditions, and health behaviors (difficulty walking 
one-quarter mile, adjusted odds ratio [OR]: 1.57; 95% CI: 1.10– 2.24]; inability to 
walk one-quarter mile, adjusted OR: 2.73; 95% CI: 1.79–4.15) [3]. Bergland et al. 
also reported a significant association (hazard ratio [HR]: 1.79; 95% CI: 1.33–2.42 
between loss of mobility and all-cause mortality in community-dwelling men and 
women in Norway. This was significant after adjustment for self-reported health, 
body mass index (BMI), smoking, and education level (HR: 1.63; 95% CI: 1.20–2.22) 
for individuals who were fastest on the timed up and go test of mobility compared 
with those who were slowest) [1]. 
 
KEY DETERMINANTS OF MALE MOBILITY 
Several modifiable and non-modifiable factors have been reported in the literature 
that impact bone, muscle, and joint health and can lead to progressive loss of 
mobility and predispose older men to poor balance, falls, and fractures (Figure 1) [4-
7]. Risk factors shown to influence mobility include older age, lower physical activity, 
obesity, strength or balance impairment, long-term use of certain medications, 
history of smoking, excessive alcohol use, nutritional deficiencies, chronic diseases 
such as obesity, diabetes mellitus, or arthritis, and low socioeconomic status [8-12]. 
Despite the known benefits of physical activity, exercise-related injuries can lead to 
mobility limitation, either directly [9] or indirectly via osteoarthritis [10]. Additionally, in 
men, the gradual decline in serum testosterone concentrations with advancing age is 
associated with limitations in mobility [13]. Given the importance of mobility and the 
plethora of risk factors among elderly men, the objective of this narrative review is to 
describe elements that are vital to healthy ageing in men and the modifiable risk 
factors that need to be managed to maintain a long, productive, and independent life 
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without limitations in mobility [4-7]. Because bone, muscle, and joint health are 
important modifiable factors that can be relatively easily enhanced to improve 
mobility, these parameters will be the focus of this review. 
  
MAINTENANCE OF BONE HEALTH 
Prevalence and Implications 
A decrease in bone strength (bone mass and bone quality) with a consequent 
increase in bone fragility and risk of fracture is termed osteoporosis [14], the most 
common metabolic bone disease in humans [15]. Osteoporosis is associated with an 
increased risk of minimal trauma fractures of the spine, proximal femur, or distal 
radius [4]. Osteoporosis-related fractures, particularly hip fractures, can result in 
significant mobility disability; among a cohort of hip fracture patients in the US, the 
proportion of patients able to walk across a room independently decreased from 75% 
prefracture to only 15% six months post hip fracture [16]. Although more common in 
women, the prevalence of osteoporosis in men aged ≥50 years is estimated at 4.3% 
in the US [17], 6.6% in Europe [18], and 5.9% in Australia [19]. Osteoporosis has 
been categorized as a worldwide epidemic by the International Osteoporosis 
Foundation (IOF) and prevalence rates are expected to increase dramatically with 
the ageing population in the coming decades, particularly in Asia. Per the IOF 
estimates, worldwide, 1 in 5 men aged over 50 years will experience an osteoporotic 
fracture [20]. By 2050, the worldwide prevalence of hip fracture is projected to 
increase by 310% in men compared with rates in 1990, and more than half of all 
osteoporotic hip fractures are expected to occur in Asia [21]. Approximately 20% to 
25% of hip fractures occur in men [21]. In a nationwide cohort study of Danish 
patients, risk of mortality following a hip fracture was found to be substantially higher 
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among men (37.1%) than women (26.4%) in the first 12 months following a hip 
fracture (male/female risk ratio 1.4; p<0.001) [22]. Mortality is also higher in men 
following nonhip minimal trauma fractures [23]. Despite its high prevalence and 
associated morbidity and increased mortality, osteoporosis in men remains 
underdiagnosed and undertreated [24]. 
 
Risk Factors for Osteoporosis 
The risk factors associated with osteoporosis are listed in Table 1 [4, 25-27]. Among 
these, lack of weight-bearing exercise, poor calcium intake, vitamin D deficiency, low 
or high body weight, cigarette smoking, excessive alcohol use, and long-term use of 
glucocorticoids are common modifiable risk factors [25]. It is now well established 
that testosterone, adrenal androgens, estrogen, growth hormone, and insulin-like 
growth factor-1 decline with advancing age, and this decline has been associated 
with both reduced bone formation and increased bone loss [28]. Among these, 
testosterone deficiency and glucocorticoid therapy are the most common secondary 
risk factors for the development of osteoporosis in men [13].  
 
Management of Osteoporosis 
Management of osteoporosis includes lifestyle measures and pharmacologic as well 
as hormonal therapy [15]. According to the National Osteoporosis Foundation, the 
universal recommendations for lifestyle measures include regular weight-bearing and 
muscle-strengthening exercises, adequate intake of calcium and vitamin D, 
cessation of tobacco use, avoidance of excessive alcohol consumption, and 
treatment of risk factors for falling [15]. While the importance of these interventions 
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and the need for supplementation changes with age, these lifestyle measures should 
be maintained throughout life to optimize bone health [25].  
 
A recent systematic review on the effects of exercise on bone mineral density (BMD) 
[29] found limited positive benefits in controlled clinical trials of exercise training of 6 
months or longer in healthy older men (aged ≥50 years) who were not being treated 
with bone-relevant pharmacologic therapy. Of the 6 studies the authors identified as 
relevant for analysis, 3 studies showed significant improvement in proximal femur 
BMD, and 3 found no or inconsistent benefits in the exercise groups. Based on the 
available literature, the authors concluded that it was not possible to recommend 
specific exercise interventions for older men that would differ from those based on 
studies in older women. However, promising effects on lumbar spine BMD have 
been observed from a high-intensity resistance training and impact exercise program 
in postmenopausal women [30], suggesting higher intensity interventions should be 
explored in populations at risk of osteoporosis and fracture. 
 
In terms of calcium and vitamin D intake (diet + supplementation), the recommended 
intakes are 1,000–1,200 mg of calcium per day and 600–800 IU/day of vitamin D for 
older men [31, 32]. Calcium is required for the mineralization of bone, and presence 
of vitamin D is required for the absorption of dietary calcium in the gut [33]. A meta-
analysis based on 8 clinical trials involving 195 hip fracture events and 2,231 total 
fracture events among 30,970 community-dwelling and institutionalized middle-aged-
to-older adults showed a statistically significant 14% reduction (95% CI: 0.75–0.98) 
in risk of total fractures and a 39% reduction (95% CI: 0.46–0.82) in risk of hip 
fractures with calcium + vitamin D supplementation [33]. A larger reduction in risk 
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was observed in the studies that included institutionalized participants compared with 
those that involved community-dwelling subjects. Another meta-analysis of studies 
restricted to community-dwelling adults failed to find a benefit for supplementation 
with calcium, vitamin D, or the combination [34]. In general, the benefits of calcium 
and vitamin D supplementation are most consistently evident among older 
individuals who are institutionalized and other individuals who are vitamin D deficient 
(serum 25-hydroxyvitamin D <50 nmol/L or <20 ng/mL) [35]. Other analyses have 
shown that evidence of a benefit is limited to those with baseline 25-hydroxyvitamin 
D <30 nmol/L [36]. 
 
For men with clinically recognized osteoporosis (based on fracture history and/or 
high fracture risk), pharmacologic treatment with bisphosphonates is recommended 
to reduce the risk of vertebral fracture [37]. Randomized, controlled trials of 
bisphosphonates in men have mainly been limited to smaller trials examining their 
effects on BMD as primary study endpoints [38]. However, one trial with intravenous 
zoledronic acid showed a 67% reduction in vertebral fractures across a two-year 
period as a primary study end point [39]. This class of drugs is approved by the US 
Food and Drug Administration as a first-line treatment for osteoporosis in men [38]. 
However, although rare, long-term bisphosphonate use (>5 years) can be associated 
with osteonecrosis of the jaw, atypical subtrochanteric and diaphyseal femur 
fractures, atrial fibrillation, and esophageal cancer [40]. Treatment with teriparatide 
(i.e., recombinant human parathyroid hormone [1–34]), is an option for men with 
severe osteoporosis at high risk of fracture due to primary or hypogonadal 
osteoporosis or osteoporosis associated with sustained systemic glucocorticoid use 
[15]. Although teriparatide was associated with a treatment-dependent increase in 
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the incidence of osteosarcoma in preclinical studies, this has not been observed in 
humans in postmarketing registries [41]. Nevertheless, the lifetime use of teriparatide 
is restricted to 18 or 24 months, depending on the country of drug registration [42-
44]. Snyder et al. have confirmed a significant positive impact of testosterone 
therapy on bone density and strength in men with low baseline levels, but larger and 
longer-duration studies are needed to determine the role of testosterone in fracture 
prevention [45]. 
 
MAINTENANCE OF MUSCLE STRENGTH 
Definition and Prevalence of Sarcopenia 
Sarcopenia is broadly defined as the “age-associated loss of skeletal muscle mass 
and function” [5]. In defining sarcopenia, the Foundation for National Institutes of 
Health (FNIH) recommended using mobility impairment as the clinically relevant 
functional state to determine meaningful weakness, and they established an FNIH 
Sarcopenia Project team to develop a robust and validated clinical definition of 
sarcopenia [46]. However, there is no clear consensus on the definition of 
sarcopenia, and several definitions are used, including the recently updated 
European Working Group on Sarcopenia in Older People (EWGSOP) definition [47], 
which primarily characterizes sarcopenia as low muscle strength; if low muscle 
quantity or quality and low physical performance are also present, it is categorized 
as severe. Sarcopenia has also been defined as “a loss of function, defined by 
walking speed or distance coupled with a loss of muscle mass” [48]. In 2016, 
sarcopenia received an ICD-10 code, which represents a major step in recognizing 
this condition as a disease [49]. In a nationally representative sample of older adults 
(age ≥60 years) in the US, the prevalence of sarcopenia among men was 16%, but 
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increased to 28% when adjusted for BMI [50]. Muscle loss in combination with high 
levels of adiposity is referred to as sarcopenic obesity [51]. 
 
Risks and Causes of Sarcopenia 
Sarcopenia is associated with increased risk of osteoporosis, falls, fractures, 
physical disability, functional decline, metabolic syndrome, and hospitalizations [52-
54]. An analysis of a large prospective cohort of 681 community-dwelling middle-
aged and older men and women was performed to determine associations between 
sarcopenia and risk of falls over 5 years [55]. Results from the analysis indicated 
variations in the association between sarcopenia and functional decline according to 
sex; men with low muscle mass had poorer muscle function compared with women 
[55]. Low muscle mass in older adults with sarcopenia has also been identified as a 
risk factor for metabolic syndrome and type 2 diabetes. A proposed mechanism is 
that significantly lower skeletal muscle mass results in greater insulin resistance and 
consequent type 2 diabetes in older patients with sarcopenia [56]. Sarcopenic 
men who are obese have even poorer outcomes. In a longitudinal study involving 
elderly subjects, those with sarcopenic obesity, who were predominantly men, were 
most likely to experience functional declines, disability, and comorbidities compared 
with lean sarcopenic or nonsarcopenic obese subjects and those with normal body 
composition [57]. Similarly, recent data from the Concord Health and Ageing in Men 
Project (CHAMP) study, a large epidemiologic study of ageing in older men (≥70 
years of age), showed an association between sarcopenic obesity and an increased 
risk of falls and fractures [58]. Compared with men without sarcopenia or obesity, 
men with sarcopenic obesity at baseline (defined using the EWGSOP criteria) had 
significantly higher 2-year fall rates (incidence rate ratio [IRR]; 1.66; 95% CI: 1.16–
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2.37), as did individuals with nonsarcopenic obesity (IRR: 1.30; 95% CI: 1.04–1.62) 
and in those with sarcopenia without obesity (IRR: 1.58; 95% CI: 1.14–2.17). 
Although no significant association was found between FNIH-defined sarcopenic 
obesity and fall rates, there was a significantly increased 6-year fracture rate 
observed in the FNIH-defined sarcopenic obesity group relative to nonsarcopenic 
obese men (HR for nonsarcopenic obesity vs sarcopenic obesity: 0.44; 95% CI: 
0.23–0.86). 
 
In addition to sarcopenia being a key contributor to disability in the elderly, 
individuals with sarcopenia have a 4-times higher risk of mortality [52]. A meta-
analysis of 17 prospective studies observed a 4-times higher risk of mortality in 
individuals with sarcopenia compared with those without sarcopenia [52]. Older men 
with sarcopenic obesity have been confirmed to have a higher risk of all-cause 
mortality compared with well-matched controls in a prospective cohort study [51].  
 
The causes of sarcopenia in elderly men are multifactorial and include declines in 
testosterone concentrations with age, decreased growth hormone, mitochondrial 
abnormalities, long-term glucocorticoid treatment, elevated pro-inflammatory 
cytokines, inactivity, and nutritional deficiencies [59]. It should also be noted that 
decreases in muscle strength/function are 2–5 times greater than decreases in 
muscle mass (Figure 2) [60, 61] and loss of muscle function significantly outpaces 
loss of muscle mass during ageing [62], demonstrating that neuromuscular changes 
beyond muscle atrophy contribute to functional decline. Indeed, increased fat 
infiltration of muscle is included in the revised EWGSOP definition as an important 
14 
 
component of sarcopenia [47] and a subject we recently reported as being 
associated with an increased risk for both osteoporosis and falls [63]. 
 
Management of Sarcopenia 
Exercise, particularly progressive resistance training (PRT), is a well-recognized 
therapeutic strategy to prevent and reverse sarcopenia. High-velocity PRT is 
particularly effective at improving lower limb muscle power, a key contributor to 
mobility [64]. In addition, vitamin D/calcium and essential amino acid protein 
supplementation have been shown to have beneficial effects [65, 66], although the 
effects for the latter have been variable across studies [66]. A recent trial suggests 
that leucine content, rather than total protein content, of supplements may be the 
primary determinant of myofibrillar protein synthesis [67]. Studies have suggested 
some additional benefits of combining dietary supplementation with exercise training 
[52], particularly for protein in conjunction with regular, prolonged PRT (≥2 weekly 
sessions for ≥6 weeks) [68]. Omega-3 fatty acid supplementation has been shown to 
enhance the effects of PRT for improving strength in older women [69], although this 
effect has not been demonstrated in older men [70]. Creatinine supplementation 
combined with resistance training increased lean mass in an elderly cohort in a 
greater magnitude compared with isolated resistance training in a 12-week, double-
blind, randomized, parallel-group, placebo-controlled trial, however, the long-term 
benefits of this intervention needs to be determined [71]. 
With respect to pharmacological therapy, there are no approved treatments for 
sarcopenia to date. Testosterone and selective androgen receptor molecules are 
being used to treat sarcopenia; however, their safety is a concern [59]. Monoclonal 
antibodies targeting either activin or myostatin, a growth hormone involved in 
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regulating muscle mass and strength, are also being investigated as potential agents 
in the treatment of sarcopenia [72]. One such agent, bimagrumab, an activin type II 
receptor antagonist, has shown efficacy and safety in increasing skeletal muscle 
mass and strength in community-dwelling older adults with sarcopenia and mobility 
limitations and increasing walking speed and mobility in those with lower baseline 
performance. These data provide strong support for the further evaluation and 
development of this class of agents [73]. 
 
MAINTENANCE OF JOINT HEALTH  
Definition and Prevalence 
Osteoarthritis is the most common chronic condition affecting the joint that can 
impact all joint tissues including the cartilage, bone, ligaments, and muscles [74]. 
The range of joint motion in patients with osteoarthritis is strongly correlated with the 
level of disability; including, walking, sitting, bending, and reclining [75]. In addition to 
mobility-related disabilities, patients with osteoarthritis suffer with chronic pain, 
aching, and stiffness and a poor quality of life [76, 77]. 
 
In the US, 33% of men in the age group of 55–64 years have a confirmed diagnosis 
of arthritis, which increases to almost 50% in men 85 years of age and older (Figure 
3) [78]. Prevalence rates of arthritis and arthritis-attributable activity limitation are 
projected to progressively increase through the year 2040, with the largest estimated 
increases occurring in adults over 65 years of age [78]. When comparing differences 
in prevalence rates based on gender, osteoarthritis has been shown to affect more 
men than women aged 50 years; however, following menopause, the rate of 
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osteoarthritis is significantly higher among women, which suggests a sex hormone 
link in the etiology of the disease [6, 79].  
 
Risk Factors for Osteoarthritis 
Osteoarthritis is a multifactorial disease with a number of modifiable and 
nonmodifiable risk factors. Modifiable risk factors include obesity, muscle strength, 
physical activity, improper movements, joint injury, and diet, while nonmodifiable risk 
factors include age, gender, genetics, ethnicity, and joint and/or bone deformities [6]. 
Individuals with osteoarthritis have a higher risk of falling, which is augmented by 
increasing age, pain level, and degree of muscle weakness [80]. 
 
Management of Osteoarthritis 
Several pharmacologic and nonpharmacologic modalities have been recommended 
for the management of osteoarthritis. With respect to the nonpharmacologic 
modalities, the American College of Rheumatology guidelines recommend that 
patients with knee and hip osteoarthritis enroll in an exercise program that includes 
aerobic, aquatic, and/or resistance exercises [81]. Additionally, dietary changes have 
been recommended to prevent or manage symptoms. These include maintaining 
dietary amounts of essential nutrients from foods and/or supplementing beyond 
recommended dietary allowances with vitamins C (ascorbic acid), D (cholecalciferol), 
E (tocopherols and tocotrienols), B3 (niacin), B12 (cobalamin), and folate (folic acid, a 
B vitamin), minerals boron and zinc, essential fatty acids, and some nonessential 
phytonutrients [82]. As obesity is one of the important modifiable risk factors of 
osteoarthritis, weight loss by combined diet and exercise is likely to be an effective 
strategy in overweight or obese patients with osteoarthritis [83]. 
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Pharmacologic treatments for hip and knee OA include adequate pain relief with 
intermittent dosing of acetaminophen, oral and topical nonsteroidal anti-inflammatory 
drugs (NSAIDs), tramadol, and intra-articular corticosteroid injections. Intra-articular 
hyaluronate injections, duloxetine, and opioids are options for individuals not 
responding to initial therapy; for adults 75 years of age or older, topical rather than 
oral NSAIDs should be considered in view of the adverse cardiovascular effects 
associated with NSAIDs [81]. However, all these therapies are, at best, moderately 
effective, and maintaining a healthy weight and regular exercise remains the most 
strongly recommended intervention [81-84]. 
 
MAINTENANCE OF BALANCE  
Prevalence and Risk Factors 
Loss of balance among older individuals results in falls, which in turn, are associated 
with fractures, soft-tissue injuries, pain, functional impairment, reduced quality of life, 
hospitalizations, and mortality [7]. According to the US Centers for Disease Control 
and Prevention, 1 in 4 older individuals (>65 years of age) fall each year and every 
19 minutes an elderly person dies from a fall [85]. Consequently, falls should be 
prevented to avoid debilitating consequences among older adults. To prevent falls, it 
is important to know the risk factors that makes an individual prone to falls, and 
these include vitamin D deficiency, impaired strength and balance, visual 
impairment, use of multiple prescription medications, solitary living, and 
environmental hazards such as poor lighting, slippery floors, and uneven surfaces 
[86]. Pain, a common symptom among older adults, has been associated with 
problems with balance or coordination, fear of falls, and a history of falls [87]. 
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Therefore, fall prevention programs should incorporate effective pain management 
strategies [87]. 
 
Prevention of Falls 
Several structured programs have been reported to be effective in preventing falls. 
One such primary prevention program, Pennsylvania’s Healthy Steps for Older 
Adults (HSOA), comprises balance assessments, education on falls, and referrals for 
fall assessments [88]. Completion of the HSOA was associated with a 17% reduction 
in falls after adjustment for fall risk factors [88]. The benefits of another approach 
called the Lifestyle integrated Functional Exercise program, wherein balance and 
strength activities are taught over 5 home visits with 2 booster visits, was assessed 
in a 3-arm, randomized, parallel trial. This study reported a 31% reduction in the rate 
of falls compared with a control program [89]. A systematic review and meta-analysis 
of randomized, controlled trials of exercise as a primary intervention for fall 
prevention in older adults (mean age ≥65 years) has reported that exercise programs 
of higher doses (>3 hours/week) and those that incorporate challenging balance 
activities are most effective for preventing falls [90]. A recent meta-analysis of 40 
randomized, controlled trials of >20,000 individuals reported that moderately 
intensive exercise 2 to 3 times per week significantly deceased the risk of falls and 
injurious falls but had no effect on fracture risk [91]. Programs that combined balance 
training and exercise resulted in a 39% reduction in falls (IRR: 0.61; 95% CI: 0.53–
0.72) compared with the 21% risk reduction found for exercise programs of any type 
among community-dwelling older adults (pooled rate ratio: 0.79; 95% CI: 0.73–0.85). 
The authors found limited evidence available supporting the effect of exercise for fall 
prevention among older adults living in residential care facilities, after stroke, or 
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following discharge from the hospital [90]. A 9-month study involving members from 
the University of Connecticut arm of the Frailty and Injuries: Cooperative Studies of 
Intervention Techniques (FICSIT) trials concluded that a maintenance program of 
balance and strength exercises might be a more effective strategy to improve 
balance and strength in older individuals rather than interventions such as Tai Chi, 
which have shown some benefits in reducing falls, probably by knee and hip 
strengthening [92]. 
 
To recommend suitable interventions that are feasible to implement in primary care 
for community-dwelling adults over 65 years of age, the US Preventive Services 
Task Force (USPSTF) published an evidence review and recommendation 
statement on interventions to prevent falls [93], which was recently updated [94]. 
This evidence-based guideline recommends exercise interventions (including 
supervised individual or group classes and physical therapy) to help prevent falls in 
older adults. The National Council on Aging has further recommended a number of 
evidence-based fall-prevention programs, including Otago, A Matter of Balance, Stay 
Active and Independent for Life, Stepping On, and Fit & Strong [95]. Although earlier 
recommendations included vitamin D supplementation, the benefits to individuals 
without osteoporosis or vitamin D deficiencies for fall prevention are unclear [94]. As 
a result, the USPSTF now recommends against vitamin D supplementation for 
prevention of falls in all community-dwelling older adults. It should be noted that 
USPSTF regards vitamin D supplementation in subjects with a deficiency as 
treatment, and these recommendations do not apply to individuals with a diagnosis 
of osteoporosis or vitamin D deficiency [94]. However, the Endocrine Society and the 
National Osteoporosis Foundation recommend consumption of fortified foods and/or 
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vitamin D supplements to ensure that recommended intake levels are reached [96, 
97]. In addition, a fall prevention program could consider individualizing interventions 
to address specific risks for each patient, such as use of anti-slip shoe devices when 
walking in slippery conditions, monitoring and adjusting psychotropic medications, 
vision correction, and pacemaker implantation in patients with cardioinhibitory carotid 
sinus hypersensitivity [98]. However, these interventions are supported by limited 
evidence. The evidence review conducted by the USPSTF found that multifactorial 
interventions customized to the patient based on an assessment of risk have a small 
benefit for the prevention of falls, and they recommend that such interventions be 
selectively offered by clinicians only to those at increased risk for falls [94]. Evidence 
for medication management and other interventions was too limited or 
heterogeneous to allow for any definitive conclusions. 
 
OVERALL CLINICAL RECOMMENDATIONS FOR PROMOTING MOBILITY AND 
HEALTHY AGEING IN MEN 
Despite the availability of greater socioeconomic facilities and resources, men have 
a shorter life span than women [99]. Premature mortality among men is often 
attributed to unhealthy lifestyle choices and lower levels of preventive health care 
[99, 100]. This combined with the numeric surge in older people presents a critical 
challenge for public health and highlights the need to specifically improve the health 
and well-being of older men [100]. In this review, we have focused on discussing 
various conditions that commonly cause limitations in mobility among older men, 
including osteoporosis, sarcopenia, osteoarthritis, and balance.  
Bone health can be improved by taking relatively simple preventive actions 
throughout the life span [25]. Preventive care should focus on regular weight-bearing 
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and muscle-strengthening exercises, adequate intake of protein, calcium, and 
vitamin D, maintaining a healthy weight, cessation of tobacco use, avoidance of 
excessive alcohol consumption, and treatment of risk factors for falling [15]. While 
the importance of these interventions and the need for supplementation change with 
age, these lifestyle measures should be maintained throughout life to optimize bone 
health [25].  
 
Men with strong masculinity beliefs are less likely to receive preventive care [99] and 
often have difficulty talking about their health problems when they occur, which 
frequently serves as a barrier to help-seeking behavior [101]. Poor health has been 
shown to be one of the most important barriers to participating in physical activity, in 
particular for older men (≥80 years) [102]. For men in particular, aches and pains, 
which are frequent consequences of physical activity, are often a barrier to further 
physical activity for men who start these activities aggressively and subsequently 
become disincentivized to participate. Additionally, social isolation is common among 
older men, particularly among those who experience mood or cognitive problems or 
who live alone [100], which has been shown to be an independent risk factor for not 
participating in physical activities [102]. Potential motivators for physical activity 
include task-related factors, such as meaningful, enjoyable, and routine activities to 
participate in, individual-level factors, including a group of peers as well as younger 
friends, and environmental factors such as places to rest and family support) [101]. A 
recent study reported that older adults should receive adequate background 
information about the rationale for performing physical exercise and clarification that 
an exercise program will be safe and provide benefits to various aspects of their 
lives, including mobility, independence, and quality of life, and will not do harm [103]. 
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Considering the benefits of engaging in community programs and men's relatively 
lower rate of involvement, there is a strong need to develop community program that 
target older men in particular, such as “Men’s Sheds” [100]. This program originated 
in Australia to create a positive impact on social engagement, adult education, and 
health and has now expanded to several other countries globally, enabling men to 
socialize and participate in learning activities. Such programs should be made 
available to all older men and should include educational programs and lifestyle 
interventions to support desirable lifestyle behaviors at all stages of life in healthy 
individuals [104].  
 
SUMMARY 
Age-related changes in bones, muscles, and joints, as well as declines in balance, 
can impact mobility in older men. There needs to be a coordinated approach among 
healthcare providers, who should work closely with older men and/or their caregivers 
to provide and re-evaluate evidence-based and effective interventions to optimize 
bone, muscle, and joint health. This is required to maintain strength, balance, and 
flexibility, which are essential for independent mobility, a key component of healthy 
ageing. Additionally, interventions involving exercise and nutrition, and specifically 
supporting participation in men, should be initiated as early as possible to prevent 
and/or reverse the progressive deterioration in bone, muscle, and joint health with 
ageing and subsequently, to delay the onset of these common and chronic diseases 
that limit mobility and prevent healthy ageing. Barriers specific to males have been 
identified, including a tendency to have difficulty discussing health-related concerns, 
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and these should be the focus of interventions to engage men in health-promoting 
behaviors that are relevant to improving bone, muscle, and joint health. 
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Table 1: Risk Factors for Osteoporosis in Men [4, 25-27] 
 
High-risk 
causes 
 
 
 
 
 
 
 
 
 
 
 
History of nontraumatic fracture (hip, vertebrae, or wrist) 
Glucocorticoid use of 5 mg or more per day for >6 months 
Hypogonadism (glucocorticoid-induced or following orchiectomy) 
Hyperparathyroidism 
Lack of weight-bearing exercise 
Poor calcium intake 
Vitamin D deficiency 
Low or high BMI 
Excess alcohol consumption 
Tobacco use 
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Medium-risk or 
infrequent 
causes 
 
Anticonvulsant drug use (phenytoin or phenobarbital) 
Rheumatoid or other inflammatory arthritis 
Multiple myeloma or lymphoma 
Hypothyroidism or hyperthyroidism 
Conditions associated with increased risk of falling (nursing home 
residence, prior fall, gait disorder, dementia, or hemiparesis) 
Family history of osteoporosis 
Cushing’s disease 
Chronic liver or kidney disease 
HIV and its treatment 
Pernicious anemia 
Gastric resection 
Mastocytosis 
BMI, body mass index; HIV, human immunodeficiency virus.  
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FIGURE CAPTIONS 
 
Fig. 1 Key determinants of male mobility [4-7] 
 
Fig. 2 Comparison of Knee Extension Strength and Leg Muscle Mass in Men 65–74 
Years of Age versus ≥75 Years of Age [60] 
aP<0.01 between age groups. 
 
Fig. 3 Prevalence of Arthritis and Attributable Activity Limitation [78] 
  
 
